Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
"Trastuzumab emtansine represents a new approach for the treatment of patients with HER2-positive breast cancer that comes from our decades of research on the HER pathway ... We are excited about the EMILIA results because trastuzumab emtansine is our first antibody drug conjugate and it may help people who still need more treatment options for this aggressive disease. We will work to submit these data to regulatory authorities as quickly as possible."
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Visit our Breast Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Shepherd, Rupert. "Roche's Trastuzumab Emtansine Has Positive Results Against Metastatic Breast Cancer." Medical News Today. MediLexicon, Intl., 30 Mar. 2012. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/articles/243609>
Shepherd, R. (2012, March 30). "Roche's Trastuzumab Emtansine Has Positive Results Against Metastatic Breast Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/243609.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.